Cellectar Biosciences Analyst Ratings
Oppenheimer Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $14
Oppenheimer Keeps Their Buy Rating on Cellectar Biosciences (CLRB)
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $7
Oppenheimer Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $14
Oppenheimer Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Raises Target Price to $14
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $7
Buy Rating Affirmed for Cellectar Biosciences on Strong Clinical Results and Improved Financial Outlook
Buy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug Pipeline
Buy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid Financials
Analysts Conflicted on These Healthcare Names: Cellectar Biosciences (CLRB), MiMedx Group (MDXG) and Marinus (MRNS)
Cellectar Biosciences Analyst Ratings
Buy Rating Affirmed for Cellectar Biosciences on Strong Clinical Results and Acquisition Potential
Cellectar Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB), Ionis Pharmaceuticals (IONS) and CVRx (CVRX)
Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB) and Seres Therapeutics (MCRB)
Oppenheimer Boosts Price Target on Cellectar Biosciences to $11 From $8, Maintains Outperform Rating
Buy Rating Backed by Pivotal Trial Catalyst and Novel Drug Delivery Platform for Cellectar Biosciences
Buy Rating on Cellectar Biosciences: Promising Clinical Study, Fast Track Designation and Strong Financial Position
Oppenheimer Remains a Buy on Cellectar Biosciences (CLRB)
No Data
No Data